✨ Free AI Report
Cytokinetics, Incorporated: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cytokinetics, Incorporated
Company Research

Cytokinetics, Incorporated: Business Overview, Financials & Competitive Analysis

Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of scientific innovations in muscle biology, advancing a pipeline of potential new medicines for patients suffering from diseases...

Analyst-debate audio for Cytokinetics, Incorporated

AskCyborg analysts argue the bull and bear cases for Cytokinetics, Incorporated across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
8/ 10Strong

Cyborg Score thesis

Transformative muscle biology platform with lead asset MYQORZO approaching multi-market approval, positioning Cytokinetics as an...

Read the full analyst-debate transcript →
Industry Specialty Cardiovascular Biopharmaceuticals
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cytokinetics, Incorporated Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Cytokinetics, Incorporated Overview

Pro stress-test →

Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of scientific innovations in muscle biology, advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. The company recently achieved FDA approval of MYQORZO™ (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy, with availability expected in the U.S. in January 2026.

Strategic Profile

Pro stress-test →

Cytokinetics stands at a pivotal inflection point in 2026, driven by the imminent EU approval of MYQORZO for obstructive hypertrophic cardiomyopathy and a rapidly advancing pipeline of muscle biology-directed therapies. Topline results from the ACACIA-HCM trial for non-obstructive HCM are expected in H1 2026, with a dual-label strategy and direct-to-consumer commercial model potentially enhancing profit margins.

Competitive Landscape

Pro stress-test →

Cytokinetics is advancing omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. The company competes in the cardiac therapeutics space with other myosin modifiers and heart failure drug developers. Direct-to-consumer commercialization for MYQORZO differentiates its approach from traditional pharma partnerships.

Industry Context

Cytokinetics, Incorporated operates in Specialty Cardiovascular Biopharmaceuticals.

Key facts

Founded: 1997 · Headquarters: South San Francisco, California · Employees: N/A · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cytokinetics, Incorporated.

  • MYQORZO FDA approval achieved with China NMPA approval already granted; EU approval decision expected Q1 2026
  • ACACIA-HCM trial topline data expected H1 2026 could double addressable market from ~120K to 200K+ patients
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Q4 2025 earnings announcement scheduled for February 24, 2026 with management call
  • January 2026MYQORZO FDA approval for symptomatic obstructive hypertrophic cardiomyopathy; January 2026 U.S. market launch initiated
  • +2 moreTrack every material event for Cytokinetics, Incorporated as it happens. Explore monitoring →
Get alerted when Cytokinetics, Incorporated has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

EntrestoHeart failure combination therapy (sacubitril/valsartan)→EmpagliflozinSGLT2 inhibitor for heart failure→VericiguatHeart failure worsening treatment→MavacamtenCardiac myosin inhibitor for hypertrophic cardiomyopathy→

Compare Cytokinetics, Incorporated with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cytokinetics, Incorporated operates in Specialty Cardiovascular Biopharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Cardiovascular Biopharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Cytokinetics, Incorporated

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cytokinetics, Incorporated and its top competitor on Cyborg Score”
“What did Cytokinetics, Incorporated do this quarter?”
“Is Cytokinetics, Incorporated a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cytokinetics, Incorporated do?+
Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of scientific innovations in muscle biology, advancing a pipeline of potential new medicines for patients suffering from diseases...
What is Cytokinetics, Incorporated's Cyborg Score?+
Cytokinetics, Incorporated has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cytokinetics, Incorporated's main competitors?+
Named competitors include Entresto, Empagliflozin, Vericiguat, Mavacamten. The full competitive landscape is in the AskCyborg report.
How can I get the full Cytokinetics, Incorporated research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cytokinetics, Incorporated research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cytokinetics, Incorporated over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.